×
About 31,564 results

ALLMedicine™ Amyotrophic Lateral Sclerosis Center

Research & Reviews  15,319 results

Cognitive reserve is associated with altered clinical expression in amyotrophic lateral...
https://doi.org/10.1080/21678421.2020.1849306
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration; Consonni M, Dalla Bella E et. al.

Dec 2nd, 2020 - Objective: Long-term life experiences, such as education, occupational attainment, leisure activities, and bilingualism, have been considered proxies of cognitive reserve (CR). In neurodegenerative disease, CR is considered as a modulator of a mor...

A novel physiologic marker of bulbar motor involvement in amyotrophic lateral sclerosis...
https://doi.org/10.1016/j.clinph.2020.09.030
Clinical Neurophysiology : Official Journal of the International Federation of Clinical Neurophysiology; Rong P, Jawdat O

Dec 1st, 2020 - To identify a novel physiologic marker of bulbar motor involvement in amyotrophic lateral sclerosis (ALS) based on jaw muscle synergies. Muscle synergies were extracted from the surface electromyographic recordings of five jaw muscles during speec...

The degeneration of upper and lower motor neuron from the perspective of clinical neuro...
https://doi.org/10.1097/WNR.0000000000001555
Neuroreport Jin J, Hu F et. al.

Nov 30th, 2020 - The aim of this study was to explore the upper motor neurons (UMN) and lower motor neurons (LMN) degeneration in amyotrophic lateral sclerosis (ALS) from the perspective of the clinical neurological examination and MRI-electromyography manifold de...

Increased Axon Initial Segment Length Results in Increased Na+ Currents in Spinal Moton...
https://doi.org/10.1016/j.neuroscience.2020.11.016
Neuroscience Jørgensen HS, Jensen DB et. al.

Nov 27th, 2020 - Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease preferentially affecting motoneurones. Transgenic mouse models have been used to investigate the role of abnormal motoneurone excitability in this disease. Whilst an increased exci...

Plasma microRNA signature in presymptomatic and symptomatic subjects with C9orf72-assoc...
https://doi.org/10.1136/jnnp-2020-324647
Journal of Neurology, Neurosurgery, and Psychiatry; Kmetzsch V, Anquetil V et. al.

Nov 26th, 2020 - To identify potential biomarkers of preclinical and clinical progression in chromosome 9 open reading frame 72 gene (C9orf72)-associated disease by assessing the expression levels of plasma microRNAs (miRNAs) in C9orf72 patients and presymptomatic...

see more →

Guidelines  9 results

Aquestive Therapeutics Receives FDA Approval for Exservan (riluzole) Oral Film
http://aquestive.com/aquestive-therapeutics-receives-fda-approval-for-exservan-riluzole-oral-film/

Nov 24th, 2019 - Aquestive Therapeutics, Inc. (NASDAQ: AQST), a specialty pharmaceutical company focused on developing and commercializing differentiated products to solve therapeutic problems, today announced that Exservan™ (riluzole) Oral Film received early-act...

Provisional best practices guidelines for the evaluation of bulbar dysfunction in amyot...
https://doi.org/10.1002/mus.26408
Muscle & Nerve; Pattee GL, Plowman EK et. al.

Jan 8th, 2019 - Universally established comprehensive clinical bulbar scales objectively assessing disease progression in amyotrophic lateral sclerosis (ALS) are currently lacking. The goal of this working group project is to design a best practice set of provisi...

MDA U.S. Neuromuscular Disease Registry
https://www.mda.org/services/neuromuscular-disease-registry
Muscular Dystrophy Association (USA)

Dec 31st, 2015 - In 2013, MDA launched the U. S.

EFNS guidelines on the clinical management of amyotrophic lateral sclerosis (MALS)--rev...
https://doi.org/10.1111/j.1468-1331.2011.03501.x
European Journal of Neurology; , Andersen PM et. al.

Sep 14th, 2011 - The evidence base for the diagnosis and management of amyotrophic lateral sclerosis (ALS) is weak. To provide evidence-based or expert recommendations for the diagnosis and management of ALS based on a literature search and the consensus of an exp...

Practice parameter update: the care of the patient with amyotrophic lateral sclerosis: ...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2764728
Neurology Miller RG, Jackson CE et. al.

Oct 13th, 2009 - To systematically review evidence bearing on the management of patients with amyotrophic lateral sclerosis (ALS). The authors analyzed studies from 1998 to 2007 to update the 1999 practice parameter. Topics covered in this section include breaking...

see more →

Drugs  31 results see all →

Clinicaltrials.gov  15,729 results

Cognitive reserve is associated with altered clinical expression in amyotrophic lateral...
https://doi.org/10.1080/21678421.2020.1849306
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration; Consonni M, Dalla Bella E et. al.

Dec 2nd, 2020 - Objective: Long-term life experiences, such as education, occupational attainment, leisure activities, and bilingualism, have been considered proxies of cognitive reserve (CR). In neurodegenerative disease, CR is considered as a modulator of a mor...

A novel physiologic marker of bulbar motor involvement in amyotrophic lateral sclerosis...
https://doi.org/10.1016/j.clinph.2020.09.030
Clinical Neurophysiology : Official Journal of the International Federation of Clinical Neurophysiology; Rong P, Jawdat O

Dec 1st, 2020 - To identify a novel physiologic marker of bulbar motor involvement in amyotrophic lateral sclerosis (ALS) based on jaw muscle synergies. Muscle synergies were extracted from the surface electromyographic recordings of five jaw muscles during speec...

The degeneration of upper and lower motor neuron from the perspective of clinical neuro...
https://doi.org/10.1097/WNR.0000000000001555
Neuroreport Jin J, Hu F et. al.

Nov 30th, 2020 - The aim of this study was to explore the upper motor neurons (UMN) and lower motor neurons (LMN) degeneration in amyotrophic lateral sclerosis (ALS) from the perspective of the clinical neurological examination and MRI-electromyography manifold de...

Increased Axon Initial Segment Length Results in Increased Na+ Currents in Spinal Moton...
https://doi.org/10.1016/j.neuroscience.2020.11.016
Neuroscience Jørgensen HS, Jensen DB et. al.

Nov 27th, 2020 - Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease preferentially affecting motoneurones. Transgenic mouse models have been used to investigate the role of abnormal motoneurone excitability in this disease. Whilst an increased exci...

Plasma microRNA signature in presymptomatic and symptomatic subjects with C9orf72-assoc...
https://doi.org/10.1136/jnnp-2020-324647
Journal of Neurology, Neurosurgery, and Psychiatry; Kmetzsch V, Anquetil V et. al.

Nov 26th, 2020 - To identify potential biomarkers of preclinical and clinical progression in chromosome 9 open reading frame 72 gene (C9orf72)-associated disease by assessing the expression levels of plasma microRNAs (miRNAs) in C9orf72 patients and presymptomatic...

see more →

News  449 results

VA Study Finds More ALS Hospitalizations With Edaravone
https://www.staging.medscape.com/viewarticle/938926

Oct 14th, 2020 - NEW YORK (Reuters Health) - Amyotrophic lateral sclerosis (ALS) patients prescribed edaravone are hospitalized more frequently, a new surveillance study in U.S. military veterans shows. Patients on edaravone had significantly higher rates of all-c...

VA Study Finds More ALS Hospitalizations With Edaravone
https://www.medscape.com/viewarticle/938926

Oct 14th, 2020 - NEW YORK (Reuters Health) - Amyotrophic lateral sclerosis (ALS) patients prescribed edaravone are hospitalized more frequently, a new surveillance study in U.S. military veterans shows. Patients on edaravone had significantly higher rates of all-c...

Drug Combo Slows Functional Decline in ALS
https://www.staging.medscape.com/viewarticle/936885

Sep 2nd, 2020 - Treatment with a fixed-dose combination of sodium phenylbutyrate and taurursodiol (AMX0035, Amylyx Pharmaceuticals) slows the rate of decline in physical function in patients with amyotrophic lateral sclerosis (ALS), according to results of the ph...

Drug Combo Slows Functional Decline in ALS
https://www.medscape.com/viewarticle/936885

Sep 2nd, 2020 - Treatment with a fixed-dose combination of sodium phenylbutyrate and taurursodiol (AMX0035, Amylyx Pharmaceuticals) slows the rate of decline in physical function in patients with amyotrophic lateral sclerosis (ALS), according to results of the ph...

New Hope for ALS
https://www.medscape.com/viewarticle/933672

Jul 8th, 2020 - Two early studies are raising hopes that some genetic forms of amyotrophic lateral sclerosis (ALS) can be treated. Both studies investigated potential benefits of suppressing the toxic activity in cells of a mutant gene (SOD1) that encodes superox...

see more →

Patient Education  27 results see all →